Head and neck cancer in 2010: Maximizing survival and minimizing toxicity

@article{Brockstein2011HeadAN,
  title={Head and neck cancer in 2010: Maximizing survival and minimizing toxicity},
  author={Bruce E. Brockstein and Everett E. Vokes},
  journal={Nature Reviews Clinical Oncology},
  year={2011},
  volume={8},
  pages={72-74}
}
Outcomes for patients with oropharyngeal cancer are determined by their tumor characteristics and associated demographics. The role of human papilloma virus-related disease for prognosis and outcomes with chemoradiotherapy is being more clearly defined. EGFR inhibitors are used in conjunction with radiotherapy, and the importance of optimizing radiation quality and minimizing toxicity is the focus of ongoing studies. 

Impact of HPV on Oropharyngeal Cancer Biology and Response to Therapy: Implications for Treatment

A review addresses the implications of findings in clinical care of a subset of patients with distinct carcinogenesis, risk factors profiles and clinical presentation that show markedly improved survival than do patients with classic OPSCC.

HPV-Associated Head and Neck Cancer.

This Commentary seeks to summarize the state of the art of the understanding of HPV-associated head and neck cancers that has emerged since the publication of seminal findings by Fakhry et al.

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy.

Aprepitant contributed to improved emesis control, enhanced DI, and better adherence to cisplatin chemotherapy in patients treated with aprepitant.

Extent of local invasion and safe resection in cT1–2 tonsil cancer

The extent of local invasion in terms of mucosal spread and deep infiltration in stage T1–2 tonsil cancer is determined in order to determine the extent of safety margin in resection.

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma

Gemcitabine and cetuximab are individually effective against HNSCC and an enhanced growth inhibitory effect may be expected when these agents are used in combination.

Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity

This review systematically reports the underlying reasons for inconsistency in disease prognosis and therapy responses among HNSCC patients from different racial populations and seeks to identify the consequences of such disparity in terms of HPV infection and its associated mutational, metabolic, and immune landscapes.

Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer

This review aims to provide considerations between surgical and non-surgical management for HPV-associated oropharyngeal squamous cell carcinoma.

A multi-objective radiomics model for the prediction of locoregional recurrence in head and neck squamous cell cancers.

A multi-classifier, multi-objective and multi-modality radiomics-based outcome prediction model for HNSCC LRR is developed and an evidential reasoning (ER)-based method to fuse the output probabilities from different classifiers and modalities in mCOM is used.

Dendritic cell‐based autologous tumor vaccines for head and neck squamous cell carcinoma

An autologous vaccine of apoptotic tumor cells (ATCs) and dendritic cells (DCs) was administered to patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) to study safety and

References

SHOWING 1-10 OF 10 REFERENCES

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

  • E. CohenD. Haraf E. Vokes
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
Gefitinib can be administered with FHX and as maintenance therapy for at least 2 years, demonstrating CR and survival rates that compare favorably with prior experience.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

  • D. RischinR. Young G. McArthur
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
HPV-associated oropharyngeal cancer is a distinct entity with a favorable prognosis compared with HPV-negative oroph throat cancer when treated with cisplatin-based chemoradiotherapy, and p16-positive patients had lower rates of locoregional failure and deaths due to other causes.

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

  • J. SalamaK. Stenson E. Vokes
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2008
IndCT before CRT reduces distant progression while maintaining high LRC, and the cohort B schedule provides the best therapeutic ratio.

Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.

  • F. FengH. M. Kim A. Eisbruch
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
Chemoradiotherapy with IMRT aiming to reduce dysphagia can be performed safely for OPC and has high locoregional tumor control rates.

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

The critical importance of radiotherapy quality on outcome of chemoradiotherapy in head and neck cancer is demonstrated, with patients who received at least 60 Gy having a markedly inferior outcome.

Clinical and functional results of deep vein resection.